BMEA / Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

Biomea Fusion is a clinical-stage biotech company developing covalent small molecule inhibitors, with its lead asset BMF-219 showing promising initial more_horizontal

A year removed from its $20 IPO of April 2021, Biomea Fusion, Inc. NASDAQ: BMEA faded into penny stock land as investors lost their appetite for high- more_horizontal

Shares of Biomea Fusion Inc. BMEA, -5.89% jumped 17% in premarket trading Monday after the clinical-stage biopharmaceutical company released new clini more_horizontal

REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company more_horizontal

BMEA develops oral covalent small molecules for cancer and diabetes. Its lead asset is a menin inhibitor. more_horizontal

Tuesday, Biomea Fusion announced encouraging mid-stage trial results for its type 2 diabetes candidate. The biotech's stock essentially doubled in val more_horizontal

Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candidate demonstrated a robust glucose-lowering respo more_horizontal

Biomea Fusion (NASDAQ: BMEA ) stock is climbing higher on Wednesday after the company announced a public offering plan. According to a press release, more_horizontal